Karen Uhlmann

High-Tech Gründerfonds Management GmbH (HTGF) is a venture capital firm founded in 2005. The firm is headquartered in Bonn, Germany.

Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany.

Part of Pfizer Inc., Coley Pharmaceutical GmbH is a German company that provides research and development in the field of natural sciences, engineering, agricultural sciences and medicine. The company is based in Berlin, Germany. The company was founded by Heather L. Davis.

Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

BioMed X GmbH is an independent research institute that conducts biomedical pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, and diagnostics. The private company is based in Heidelberg, Germany. The German company sponsors these projects with pharmaceutical partners such as Merck, Boehringer Ingelheim, Johnson & Johnson, AbbVie, and Roche. Talented early-career scientists from all over the world are recruited to work on these projects. The company combines crowdsourcing with local incubation to provide creative solutions to big biomedical research challenges. Each research team has access to state-of-the-art research infrastructure and is guided by experienced mentors from academia and industry. The company was founded in 2013 by Christian Tidona, who has been the CEO since 2013.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands.

BioMedx Group, Inc. operates as a medical technology company transforming the cosmetic surgery consultation services. The firm engages in product development focus on the modeling and simulation of the human face for aesthetic and facial reconstruction applications. The company was founded by Rudy A. Mazzocchi and is headquartered in Baltimore, MD.

STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark.

The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris.

Sanofi-Aventis Deutschland GmbH engages in the development, manufacture, and packaging of medicines, as well as pharmaceutical products. It also focuses on the research into the causes of diseases and the search for its drug treatment. The company was founded in 2004 and is headquartered in Frankfurt, Germany.

Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland.

Scienion AG develops and provides DNA biochips and protein microarrays. It provides its customers in the pharmaceutical, biotech, diagnostic and reagent supply markets, as well as in academic research institutions with products, and services to facilitate confidence and efficiency in aspects of its applications. The company was founded by Holger Eickhoff in 2000 and is headquartered in Dortmund, Germany.

BIO Deutschland is a business association for the biotechnology industry. The private company is based in Berlin, Germany. The German company was founded by Peter Heinrich, Horst Domdey. Viola Bronsema has been the CEO of the company since 2006.

Energy Impact Partners LLC (Energy Impact Partners) is a private equity firm founded in 2014 by Steven Hellman. The firm is headquartered in New York.

WMT AG is a German research company that specializes in developing cancer therapies. WMT was founded in 2020 by Yves Guillermet and Claus Kremoser, with Claus Kremoser serving as the CEO since 2020.

tado GmbH develops and markets residential heating control and energy management systems. The firm specializes in the design and installation of heating and cooling technologies in houses and apartments. It offers solutions under the tado brand, with focus on meeting the needs of residential units with own gas central and district heating systems. The company was founded by Christian Deilmann, Johannes Schwarz and Valentin Sawadski in 2011 and is headquartered in Munich, Germany.

Greenbird Integration Technology AS provides digital business development, IT strategy, architecture modeling, development, enterprise architecture governance and business process management services. It serves to the utilities and energy sector, banking and financial services, telecom and media and gas industries. The company was founded by Fredrik Omland in 2010 and is headquartered in Oslo, Norway.

Middle Peak Medical, Inc. develops implants for treatment of mitral valve disease. Its technology has application in both percutaneous catheter-based intervention and in minimally invasive or open-heart cardiac surgery. The company was founded by Michael D. Lesh and Alexander Khairkhahan in 2011 and is headquartered in Palo Alto, CA.

Böhm Fertigungstechnik Suhl GmbH manufactures mechanical components, electronic equipment, and special machinery. The company was founded in 1991 and is headquartered in Zella-Mehlis, Germany.

Statkraft Ventures GmbH (Statkraft Ventures) is a venture capital subsidiary of Statkraft Markets GmbH, itself a subsidiary of Statkraft AS, ultimately owned by the Government of Norway, founded in 2015. The firm is headquartered in Dusseldorf, Germany, with an additional office in Oslo, Norway.

Implandata Ophthalmic Products GmbH develops diagnosis tool for glaucoma therapy. Its technology Pro-IOP is an eye pressure measurement system consists of an implantable micro sensor, responsible for pressure sensing, an external hand held device, which is transferring energy to the micro sensor telemetrically and which is responsible for data read out and storage and a GSM module which can be connected with the hand held device for transfer of measurement data to a database, which can be accessed by the eye doctor in order to get information about the disease status of the patient. The company was founded by Max Georg Ostermeier and Stefan Meyer in January 2010 and is headquartered in Hannover, Germany.

Natural Dental Implants AG provides dental technology products and services. The firm specialized in the development of Replicate, a non-surgical tooth replacement system designed to alternative preserve alveolar bone and adjacent teeth. It offers an alternative solutions to traditional dental implants and three unit dental bridges, with focus on three-dimensional image and impression, natural healing, and temporary and permanent crown features. The company was founded by Ruedger Rubbert and Lea Ellermeier Nesbit in 2009 and is headquartered in Berlin, Germany.

AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany.

Part of Ensoma, Inc., Twelve Bio is a Danish company that seeks to expand the breadth of CRISPR-based gene-editing medicines to transform the management of serious diseases. The company is based in Copenhagen, Denmark. Twelve Bio uses its insights into nuclease structure and function to design highly precise and nimble CRISPR-Cas12 candidates for therapeutic application. The company will continuously advance its platform and understanding of Cas enzymes to address the needs of patients worldwide. The company was founded by Stefano Stella, Guillermo Montoya. Twelve Bio was acquired by Ensoma, Inc. on February 09, 2023.

Neovii Biotech GmbH develops and markets biopharmaceutical products in the field of transplantation. The company was founded in 2003 and is headquartered in Gräfelfing, Germany.

Humedics GmbH operates as a research-based medtech company. It focuses on rapid and precise lover function measurement using LiMax, a breath analysis technology. The company was founded by Martin Stockman, Erwin de Bujizer, and Karsten Heyne in 2009 and is headquartered in Berlin, Germany.

IBB Beteiligungsgesellschaft mbH (IBB Ventures) is the wholly-owned venture capital subsidiary of Investitionsbank Berlin. The firm was founded in 1997 to foster the development of regional businesses in selected areas and to strengthen the local labor market. The firm is headquartered in Berlin, Germany.

Inflectis Bioscience SAS develops therapeutics for the treatment of protein misfolding diseases. The firm engages in the development of new chemical series for the treatment of non-orphan diseases whose etiology also lies in the accumulation of misfolded proteins. The company was founded in September 2013 by Philippe Guedat and Pierre Miniou and is headquartered in Nantes, France.